Megestrol Acetate Oral Suspension
"Nov. 21, 2012 -- Women over age 40 are often urged to get yearly mammograms with the promise that early detection is their best hope for beating breast cancer.
But a new study published in The New England Journal of Medicine su"...
Megestrol Acetate Oral Suspension
Megestrol Acetate Oral Suspension Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Megestrol acetate oral suspension contains a form of the hormone progesterone and is used to treat anorexia, wasting (cachexia), or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). This medication is available in generic form. Common side effects include diarrhea, weight gain, nausea, rash, impotence, insomnia, mood swings, sweating, breakthrough menstrual bleeding, high blood pressure, and flatulence.
The recommended adult initial dosage of megestrol acetate oral suspension is 800 mg/day (20 mL/day). Megestrol acetate oral suspension may interact with other drugs. Tell your doctor all medications and supplements you use. Megestrol acetate should not be used during pregnancy. It may cause fetal harm. Because of the potential for adverse effects on a nursing baby, breastfeeding should be discontinued if megestrol acetate oral suspension is required.
Our megestrol acetate oral suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Megestrol Acetate Oral Suspension FDA Prescribing Information: Side Effects
Clinical Adverse Events: Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing megestrol acetate oral suspension.
% of Patients Reporting
|Open Label Trial
Adverse events which occurred in 1 to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.
Hemic and Lymphatic System - leukopenia
Special Senses - amblyopia
Postmarketing - Postmarketing reports associated with megestrol acetate oral suspension included throm-boembolic phenomena including thrombophlebitis and pulmonary embolism and glucose intolerance (see WARNINGS and PRECAUTIONS sections).
Read the entire FDA prescribing information for Megestrol Acetate Oral Suspension (Megestrol Acetate Oral Suspension)
Additional Megestrol Acetate Oral Suspension Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.